Staufen1s Role As a Splicing Factor and a Disease Modifier in Myotonic Dystrophy Type I
Overview
Authors
Affiliations
In a recent issue of , we reported that the double-stranded RNA-binding protein, Staufen1, functions as a disease modifier in the neuromuscular disorder Myotonic Dystrophy Type I (DM1). In this work, we demonstrated that Staufen1 regulates the alternative splicing of exon 11 of the human Insulin Receptor, a highly studied missplicing event in DM1, through Alu elements located in an intronic region. Furthermore, we found that Staufen1 overexpression regulates numerous alternative splicing events, potentially resulting in both positive and negative effects in DM1. Here, we discuss our major findings and speculate on the details of the mechanisms by which Staufen1 could regulate alternative splicing, in both normal and DM1 conditions. Finally, we highlight the importance of disease modifiers, such as Staufen1, in the DM1 pathology in order to understand the complex disease phenotype and for future development of new therapeutic strategies.
Large-scale evaluation of the ability of RNA-binding proteins to activate exon inclusion.
Schmok J, Jain M, Street L, Tankka A, Schafer D, Her H Nat Biotechnol. 2024; 42(9):1429-1441.
PMID: 38168984 PMC: 11389820. DOI: 10.1038/s41587-023-02014-0.
Adaptation of RiPCA for the Live-Cell Detection of mRNA-Protein Interactions.
Soueid D, Garner A Biochemistry. 2023; 62(23):3323-3336.
PMID: 37963240 PMC: 11466511. DOI: 10.1021/acs.biochem.3c00334.
RNA-binding protein signaling in adult neurogenesis.
Chan J, Sanchez-Vidana D, Anoopkumar-Dukie S, Li Y, Benson Wui-Man L Front Cell Dev Biol. 2022; 10:982549.
PMID: 36187492 PMC: 9523427. DOI: 10.3389/fcell.2022.982549.
MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Wu J, Lu G, Wang X Am J Cancer Res. 2022; 11(12):5864-5880.
PMID: 35018230 PMC: 8727814.